Database Query Results : , , YAP/TEAD

YAP/TEAD, YAP/TEAD activity: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
YAP (Yes-associated protein) and TEAD (TEA domain transcription factors) are key components of the Hippo signaling pathway, which plays a crucial role in regulating cell growth, proliferation, and apoptosis.
Activation of YAP: In normal conditions, the Hippo pathway inhibits YAP activity, preventing excessive cell growth. However, when the Hippo pathway is inactivated (due to mutations or other factors), YAP becomes activated. This leads to increased cell proliferation and survival, contributing to tumorigenesis.
TEAD as a Transcription Factor: YAP interacts with TEAD proteins to drive the expression of target genes that promote cell growth and inhibit apoptosis. This YAP/TEAD complex is often found to be overactive in several types of cancer, including liver, breast, and lung cancers.
Scientific Papers found: Click to Expand⟱
741- Bor,    Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
MOB1↓, PD-L1↑, p‑YAP/TEAD↝, IFN-γ↓, sFasL↑, Perforin↓, GranA↓, GranB↓, GNLY↓, PD-1↑,
684- EGCG,    Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation
- in-vitro, CRC, NA
eff↑, Akt↓, VEGFR2↓, STAT3↓, P53↓, Hippo↓, YAP/TEAD↑,
1125- LT,    Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity
- in-vitro, BC, NA
YAP/TEAD↓, TAZ↓, MSCmark↓, EM↑, TumCMig↓,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
1042- MEL,    Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H460 - in-vitro, Lung, LLC1
PD-L1↓, YAP/TEAD↓, TAZ↓, TumCG↓,
2247- MF,    Effects of Pulsed Electromagnetic Field Treatment on Skeletal Muscle Tissue Recovery in a Rat Model of Collagenase-Induced Tendinopathy: Results from a Proteome Analysis
- in-vivo, Nor, NA
*Glycolysis↓, *LDHB↑, *NAD↑, *ATP↑, *antiOx↑, *ROS↑, *YAP/TEAD↑, *PGC-1α↑, *TCA↑, *FAO↑, *OXPHOS↑,
3083- RES,    Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
YAP/TEAD↓, Rho↓, FAK↓, MMP9↓, ChemoSen↑, RAS↓, ROCK1↓, TumCI↓, TumMeta↓,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
2234- SK,    Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1
- in-vitro, GC, NA
TumCP↓, TumCI↓, TumCMig↓, cMyc↓, YAP/TEAD↓,
3107- VitC,    Repurposing Vitamin C for Cancer Treatment: Focus on Targeting the Tumor Microenvironment
- Review, Var, NA
Risk↓, *ROS↓, ROS↑, VEGF↓, COX2↓, ER Stress↑, IRE1↑, JNK↑, CHOP↑, Hif1a↓, eff↑, Glycolysis↓, MMPs↓, TumMeta↓, YAP/TEAD↓, eff↑, TET1↑,
1751- WBV,    Yoda1 Enhanced Low-Magnitude High-Frequency Vibration on Osteocytes in Regulation of MDA-MB-231 Breast Cancer Cell Migration
- in-vitro, BC, MDA-MB-231 - in-vitro, AML, RAW264.7
BMD↑, YAP/TEAD↑, TumCG↓, Strength↑, TumCI↓, Fas↑, Ca+2↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↑, 1,   HO-1↓, 1,   lipid-P↓, 1,   NRF2↓, 1,   NRF2↑, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

CDC2↓, 1,   MEK↓, 1,   MMP↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 2,   p‑cMyc↑, 1,   Glycolysis↓, 1,  

Cell Death ⓘ

Akt↓, 3,   APAF1↑, 1,   BAX↑, 2,   Bcl-2↓, 1,   Bcl-xL↓, 1,   BIM↓, 1,   Casp↑, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   cl‑Casp8↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 1,   DR5↑, 1,   Fas↑, 1,   GranA↓, 1,   GranB↓, 1,   Hippo↓, 1,   hTERT/TERT↓, 1,   iNOS↓, 1,   JNK↑, 2,   MAPK↓, 1,   MDM2↓, 1,   NICD↓, 1,   Perforin↓, 1,   sFasL↑, 1,   survivin↓, 2,   Telomerase↓, 1,   YAP/TEAD↓, 7,   YAP/TEAD↑, 2,   p‑YAP/TEAD↝, 1,  

Transcription & Epigenetics ⓘ

HATs↑, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 2,   IRE1↑, 1,  

Autophagy & Lysosomes ⓘ

LC3B-II↑, 1,   LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   P53↓, 1,   P53↑, 2,   cl‑PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   P21↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 2,   ERK↓, 2,   p‑GSK‐3β↓, 1,   HDAC↓, 1,   MSCmark↓, 1,   mTOR↓, 1,   NOTCH1↓, 1,   PI3K↓, 2,   RAS↓, 2,   STAT3↓, 1,   TAZ↓, 3,   TumCG↓, 2,   Wnt↓, 1,  

Migration ⓘ

AEG1↓, 1,   Ca+2↑, 2,   CD31↓, 1,   E-cadherin↑, 1,   EM↑, 1,   FAK↓, 1,   MMP2↓, 1,   MMP9↓, 2,   MMPs↓, 2,   MOB1↓, 1,   N-cadherin↓, 1,   Rho↓, 1,   ROCK1↓, 1,   TET1↑, 1,   TIMP1↑, 1,   TIMP2↑, 1,   TumCI↓, 3,   TumCMig↓, 2,   TumCP↓, 2,   TumMeta↓, 3,   uPA↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   Hif1a↓, 2,   VEGF↓, 3,   VEGFR2↓, 3,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CXCR4↓, 1,   GNLY↓, 1,   IFN-γ↓, 2,   IFN-γ↑, 1,   IL10↓, 1,   IL2↑, 1,   Inflam↓, 1,   MDSCs↓, 1,   NF-kB↓, 1,   p‑NF-kB↑, 1,   PD-1↑, 1,   PD-L1↓, 1,   PD-L1↑, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↓, 1,   ChemoSen↑, 2,   eff↑, 3,   MDR1↓, 1,   RadioS↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 1,   BMD↑, 1,   hTERT/TERT↓, 1,   PD-L1↓, 1,   PD-L1↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   Risk↓, 1,   Strength↑, 1,  
Total Targets: 129

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   OXPHOS↑, 1,   ROS↓, 1,   ROS↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

FAO↑, 1,   Glycolysis↓, 1,   LDHB↑, 1,   NAD↑, 1,   TCA↑, 1,  

Cell Death ⓘ

YAP/TEAD↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 1,  

Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 16

Scientific Paper Hit Count for: YAP/TEAD, YAP/TEAD activity
2 Luteolin
1 Boron
1 EGCG (Epigallocatechin Gallate)
1 Melatonin
1 Magnetic Fields
1 Resveratrol
1 Silymarin (Milk Thistle) silibinin
1 Shikonin
1 Vitamin C (Ascorbic Acid)
1 Whole Body Vibration
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:340  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page